Zepbound injection pen (Shutterstock)
Lilly exec points to Medicare as more pay full list price for Zepbound than Mounjaro
A larger share of Medicare patients are having to pay the full list price for Lilly’s obesity drug Zepbound than for Mounjaro, a top executive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
